« Return to News | Drug Sponsors

Pension fund sues Cephalon over Valeant buyout

Friday, April 1, 2011 01:54 PM

A Pennsylvania pension fund has filed a lawsuit and accused Cephalon officials of “failing to act” in the best interests of investors regarding a $5.7 billion buyout bid by rival Mississauga, Ontario-based Valeant Pharmaceuticals International, according to a Bloomberg report.

Cephalon, a maker of sleep and pain drugs, said yesterday that it will consider the bid next week. In its complaint, the pension fund claimed the company has been shortchanging shareholders by not considering the $73-a-share hostile offer.

Lawyers for the Dauphin County pension plan said the company’s directors are “failing to act in the interest of Cephalon stockholders” by turning away repeated offers by the Canadian drugmaker, as reported in Bloomberg.

The fund wants a Delaware judge to force Cephalon’s board to consider Valeant’s offer and bar use of the company’s so-called poison-pill defense to frustrate the buyout bid, according to the lawsuit. That defense makes acquisitions more expensive.

Natalie de Vane, a Cephalon spokeswoman, said yesterday in a phone interview, “Our board of directors will meet early next week to consider Valeant’s proposal.”

The case is County of Dauphin Retirement Plan v. Winger, CA NO. 6332, Delaware Chancery Court (Wilmington).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.